Factor Xa
Signaling Pathway Map
Research Area
Inhibitory Selectivity
Factor Xa Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S3002 |
RivaroxabanRivaroxaban is a direct inhibitor of Factor Xa with Ki and IC50 of 0.4 nM and 0.7 nM in cell-free assays, respectively. It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (IC50 >20 μM). |
a, BMDMs were pretreated with or without 10 μM FXa inhibitor rivaroxaban or 10 μM DPP4 inhibitor KR62436, followed by incubation for 4 h with rFX or rDPP4 alone or in combination. Mcp1 mRNA was then quantified. n = 4 technical replicates per group; mean ± s.e.m.; *P < 0.05 by one-way ANOVA.
|
|
| S1593 |
ApixabanApixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. |
The peak fluorescence of each time course at the specified drug concentration are plotted as a function of concentration of apixaban. Dose-response curve was fitted to the Hill equation.
|
|
| S7280 |
Edoxaban tosylate MonohydrateEdoxaban is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug. |
||
| S5388 |
BetrixabanBetrixaban is a new, long-acting, oral and selective Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation. |
||
| S5389 |
Betrixaban maleateBetrixaban maleate is the maleate salt form of Betrixaban, which is a Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S3002 |
RivaroxabanRivaroxaban is a direct inhibitor of Factor Xa with Ki and IC50 of 0.4 nM and 0.7 nM in cell-free assays, respectively. It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (IC50 >20 μM). |
a, BMDMs were pretreated with or without 10 μM FXa inhibitor rivaroxaban or 10 μM DPP4 inhibitor KR62436, followed by incubation for 4 h with rFX or rDPP4 alone or in combination. Mcp1 mRNA was then quantified. n = 4 technical replicates per group; mean ± s.e.m.; *P < 0.05 by one-way ANOVA.
|
|
| S1593 |
ApixabanApixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. |
The peak fluorescence of each time course at the specified drug concentration are plotted as a function of concentration of apixaban. Dose-response curve was fitted to the Hill equation.
|
|
| S7280 |
Edoxaban tosylate MonohydrateEdoxaban is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug. |
||
| S5388 |
BetrixabanBetrixaban is a new, long-acting, oral and selective Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation. |
||
| S5389 |
Betrixaban maleateBetrixaban maleate is the maleate salt form of Betrixaban, which is a Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation. |
